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Introduction                                                             
DNA repair is an essential physiological mechanism for 
maintaining genomic integrity in nucleated cells. The 
DNA damage response (DDR) pathway has evolved to be 
a complex, sensitive, highly integrated and 
interconnected pathway which can trigger a variety of 
cellular responses including DNA repair, cell cycle arrest 
and apoptosis [1]. Central to the DDR is the Ataxia 
telangiectasia mutated (ATM) gene product, a large 
protein kinase, which is responsible for the initiation of a 
signalling cascade that is triggered following double 
stranded DNA damage. The importance of the role of 
ATM is highlighted by its functional loss in the disease 
Ataxia Telangiectasia (A-T), also known as Louis-Barr 
syndrome, caused by hereditary mutations in the ATM 
gene. A-T is a rare autosomal recessive disorder 
characterized by immune deficiency, hypersensitivity to 
ionizing radiation (IR), and a predisposition to certain 
cancers [2]. A-T patients usually exhibit only partial 
deficiency of ATM protein, the residual levels varying 
between 1 and 17% of the normal level of ATM (3]. 
Usually, affected individuals present in early childhood 
with progressive cerebellar ataxia, which may initially be 
misdiagnosed as cerebral palsy of the ataxic type. Later, 
conjunctival telangiectasias and immune disturbances 
develop. Progressive neurological degeneration (without 
mental retardation) affects a significant proportion of 
older patients [4]. Thymus hypoplasia and complete loss 
or severe reduction in IgG2 or IgA levels are seen in the 
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Abstract 
The Ataxia Telangiectasia Mutated gene encodes the ATM protein, a key element in the DNA damage response 
(DDR) signalling pathway responsible for maintaining genomic integrity within the cell. The ATM protein 
belongs to a family of large protein kinases containing the phosphatidylinositol-3 catalytic domain, including 
ATM, ATR and PI3K. ATM provides the crucial link between DNA damage, cell cycle progression and cell 
death by first sensing double stranded DNA breaks and subsequently phosphorylating and activating other 
downstream proteins functioning in DNA damage repair, cell cycle arrest and apoptotic pathways. Mammalian 
cells are constantly challenged by genotoxic agents from a variety of sources and therefore require a robust 
sensing and repair mechanism to maintain DNA integrity or activate alternative cell fate pathways. This review 
covers the role of ATM  in DDR signalling and describes the interaction of the ATM kinase with other proteins in 
order to fulfil its various functions. Special emphasis is given to how the growing knowledge of the DDR can 
help identify drug targets for cancer therapy, thus providing a rationale for exploiting the ATM pathway in 
anticancer drug development. Moreover, we discuss how a network modelling approach can be used to identify 
and characterise ATM inhibitors and predict their therapeutic potential.  
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majority of patients. Recurrent sinopulmonary infections, 
related to the accompanying immune deficiency and 
gonadal dysgenesis are also common among A-T 
patients [3, 5]. Predisposition to malignancy, especially 
haematological cancers, is one of the hallmarks of the A-
T syndrome with cancer being the most frequent cause of 
death of A-T patients. This link between A-T and some 
forms of cancer was first observed by Reed WB et al in 
1966 [7] who looked at incidences of familial and sporadic 
cancers in homozygous A-T patients as well as in 
heterozygous carriers. Normally, lymphomas in A-T 
patients tend to be of B-cell origin, whereas the 
leukemias are of T-cell origin [8]. Association between 
A-T status and susceptibility to cancer has been found in 
a variety of tumours to differing degrees and appears to 
be dependent on the type of ATM mutation, e.g. 
missense variants or truncating mutations [9] as well as 
the nature of the mutations e.g. germ line or somatic A-T 
[10, 11] At the cellular level, cultured A-T cells are 
abnormally resistant to inhibition of DNA synthesis by 
IR [6]. 
It is notable that heterozygous carriers of ATM 
mutation are relatively common amongst the general 
population, with estimates varying between 1.4 % and 2.2 
%, and as high as 12.5 % in populations with a marked 
founder effect [5, 12, 13]. A-T patients from non-
consanguineous families are usually compound 
heterozygotes. Carriers of defective ATM alleles, 
although generally considered asymptomatic, have been 
found to have an increased risk of death at any age due to 
all causes including cancer and ischemic heart disease [5, 
13]. The role of defective ATM alleles has been clearly 
demonstrated in a proportion of familial breast cancer 
and colorectal cancer cases [14, 15]. Despite the 
heterogeneity in the clinical presentation of the A-T 
syndrome resulting in the initial finding of at least 4 
complementation groups [16], subsequent linkage 
analysis showed that they all map to the same genomic 
location on chromosome 11 (11q22.3) containing the 
ATM gene [17, 18].  
The ATM gene is extremely large - the full genomic 
region spans 150 Kb and consists of 66 exons [19]. ATM 
shares a bidirectional promoter with a gene called NPAT, 
which is located around 0.55 kB upstream of the ATM 
start codon. NPAT is required for progression through 
G1/S and entry into S-phase of cell cycle and has also 
been shown to positively regulate ATM [20, 21]. The 
ATM promoter region has been found to be TATA-less, 
but includes CCAAT boxes and several other important 
promoter sites including CREB, SP1, AP-2, GCF [22, 23, 
24]. However, there is some evidence of the existence of 
another putative promoter region immediately upstream 
of the first coding exon which includes a TATA box [25]. 
This may contribute to the basal level expression of the 
ATM. In the past, several groups, including our own, 
have analysed the ATM promoter region to study its 
transcriptional activity and to elucidate ATM expression 
patterns and have found that the promoter activity is 
tissue specific, and inducible under certain conditions. 
For example, Gueven N et al in 2001 [26] reported 
downregulation of ATM expression upon treatment with 
Epidermal Growth Factor, while Hirai Y et al [27] in the 
same year demonstrated upregulation of ATM gene 
expression upon irradiation of lymphoblastoid cell lines. 
Recently, we reported induction of ATM expression 
upon inhibition of its kinase activity [28, 29]. Additional 
studies in vivo and in vitro as well as computer-aided 
mathematical modeling studies on ATM also revealed 
that ATM regulation could be tissue dependent, and may 
be subject to significant transcriptional regulation both at 
the promoter and mRNA level [30, 31, 32, 33].  
The ATM gene encodes a Serine/Threonine protein 
kinase belonging to the PhosphatidyInositol 3 Kinase 
like Kinase (PIKK) super family. The ATM protein is a 
~350kD nuclear protein comprised of 3056 amino acids 
[34, 35] with its kinase activity located within the 
Phosphatidylinositol 3/4 catalytic domain and a FRAP-
ATM-TRRAP (FAT) domain located towards the C-
terminus (FATC) [35]. A leucine zipper motif has also 
been identified in the region spanning residues 1217 to 
1238, which is thought to be involved in protein-protein 
interactions [36]. ATM is generally regarded as 
constitutively expressed protein and is held in an inactive 
homodimeric or higher order multimeric form. Upon 
DNA damage, for example by IR treatment, the pre-
existing homodimeric ATM complexes undergo rapid 
autophosphorylation at residues Ser367, Ser1893 and 
Ser1981 within the FAT domain. This leads to dimer 
dissociation and the release of the active ATM 
monomers without an absolute increase in total ATM 
protein levels [37]. A complete list of known 
phosphorylated residues of ATM is given in Table 1. 
 
Table 1. ATM phosphorylational mapping 
 
Residue modified Position Reference 
Serine 72 (40) 
Serine 85 (40) 
Serine 86 (40) 
Serine 367 (38) 
Serine 373 (40) 
Serine 1883 (41) 
Serine 1893 (38) 
Serine 1981 (37) 
Serine 1985 (40) 
Serine 2996 (42) 
Serine 72 (40) 
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However, of those listed, only the 
autophosphorylation sites at Serine 367, 1893 and 1981 
have been fully characterised and play a role in ATM 
activation [37, 38, 39]. The remainder of the 
phosphorylation sites were identified through large scale 
proteomic analysis [40, 41, 42] and their role in regulating 
the function of the protein warrants further study. Once 
activated, ATM and other members of the PIKK family 
phosphorylate key substrates involved in DNA damage 
repair, DNA replication, cell cycle checkpoint arrest and 
apoptosis [43, 44], providing an important functional link 
between DNA damage recognition and appropriate 
cellular response to the damage.. In terms of its role in 
cell cycle regulation, ATM interacts with a number of 
downstream substrates including proteins that activate 
the  G1, S  or G2/M  checkpoints,  as set out  in  Table 2.  
This functional link between the two pathways is very 
specific and tightly regulated at multiple levels. A 
simplified version of this pathway is shown in Figure 1. 
DNA damage activates sensor proteins and transducers 
that recognize, relay and amplify the damage signal 
following genotoxic insult, and triggers different cellular 
responses depending on the level of DNA damage. ATM 
also has a critical role in homologous repair during 
normal meiotic recombination events [45]. 
 
Table 2. ATM substrates in different phases of the cell cycle [14, 46] 
 
  
Several early studies reported no quantitative changes 
in the expression levels and localisation of ATM 
throughout the cell cycle and upon DNA damage [47, 48]. 
However later studies reported that under certain 
conditions the expression of ATM may be altered, 
accompanied by a corresponding change in ATM activity 
[26, 32, 49]. 
 
The ATM signalling pathway during DDR 
 
The ATM signalling pathway is triggered after double 
stranded DNA damage and provides a robust and very 
sensitive detection mechanism which generates 
responses that can cause cell cycle arrest, initiate DNA 
repair or induce apoptosis. The numerous substrates 
involved in the ATM signalling network are illustrated in 
Figure 2. There is considerable cross-talk between the 
different ATM substrates and several of them provide 
functions in more than one cellular response, which 
ensures a tightly co-ordinated and regulated cellular 
response. Following DNA damage, a variant form of 
histone, called H2AX, previously buried within the 
chromatin microenvironment, becomes exposed due to 
changes in the higher order of chromatin structure. This 
is caused by relaxation and unwinding of the local DNA 
supercoil due to the DNA breaks and recruitment of 
RAD51, exerting local topological changes. The 
phosphorylation of H2AX on Serine 139 (referred to as 
γH2AX) by ATM represents one of the earliest events in 
the DDR and acts as a docking site for a variety of other 
proteins involved in the DDR [56].  MRE11, RAD50 and 
NBS1 (collectively called the MRN complex) play a 
central and multifunctional role in the repair of double 
stranded DNA breaks and DNA recombination [56, 57, 
58]. 
The MRE11 subunit of the complex has double strand 
exonuclease activity which excises the damaged DNA to 
allow for synthesis of a corrected strand. The RAD50 
protein has ATPase activity which along with RAD51, 52 
and 54, is thought to be involved in holding the two 
broken DNA ends together and also facilitate searches 
for homology in order to initiate recombination. NBS1 
plays an important role of recruiting the MRN complex 
to the damaged site, binding to the γH2AX and also 
facilitating the binding of ATM to the complex and its 
subsequent autophosphorylation and activation [56]. 
Another ATM substrate involved in the DNA repair 
component of DDR is BRCA1, which acts as a 
scaffolding protein at the damaged site for recruitment of 
multiple protein complexes involved in DNA repair [59]. 
These initial events in turn activate other pre-existing 
inactive ATM molecules by exposing their binding sites 
and triggering dimer to monomer dissociation. The 
activation of ATM also involves its acetylation by a 
histone acetylase called Tip60 which was found to 
acetylate ATM on residue 3016, an event that is thought 
to precede autophosphorylation [60]. Activated ATM 
links the DNA damage response to the cell cycle pathway 
partly via the tumour suppressor protein P53. ATM 
causes the stabilization and activation of P53 primarily by 
phosphorylating P53 directly at Serine 15 [50]. ATM 
further contributes to P53 stabilisation by 
phosphorylating MDM2 at Serine 395, thereby triggering 
the degradation of this negative regulator of P53. 
Recently, in an in-vivo mouse study, the phosphorylation 
of the equivalent serine (Serine 394 in murine MDM2) by 
ATM was shown to be a critical event in the DNA 
damage induced stabilisation and activation of P53 [53]. 
In addition, ATM phosphorylates the Serine/Threonine 
checkpoint kinases Chk1 and Chk2 following DNA 
damage [61, 62], and these protein kinases in turn 
phosphorylate P53 on Serine 20 and contribute further to 
G1 G1/S S G2/M 
P53 
Mdm2 
Nbs1 
P53 
cAbl 
Rad51 
RPA 
Chk2 
FANCD2 
H2AX 
BRCA1 
CtIP 
MRN 
Chk1 
Chk2 
Rad17(RFC) 
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its stabilization [63]. Once P53 is activated, it induces the 
expression of many proteins, including the endogenous 
inhibitors of the cyclin-cdk complexes e.g. 
p21Cip1/Waf1 and p27Kip  [61, 63]. These early events in 
the DDR lead to checkpoint arrest in the G1 phase of the 
cell cycle. In addition to phosphorylating P53, checkpoint 
kinases Chk1 and Chk2 phosphorylate and inactivate 
Cdc25 phosphatases, which prevents the activation of 
cyclin-Cdk complexes and mitosis-promoting factor, 
leading to cell cycle arrest at the G2/M transition [62]. 
Figure 3 demonstrates the interplay between the DNA 
damage response and the cell cycle. Depending upon the 
level of DNA damage, activated ATM may also cause 
induction of apoptosis in a P53 dependent or independent 
manner, and involving the ATM substrates E2F1[52], 
checkpoint kinases Chk1 and Chk2 [63, 64], as well as p73 
and c-Abl  mediated  pathways [65, 66] as shown in 
Figure 2. 
ATM deficient cells are unable to detect the levels of 
DNA damage which would otherwise result in activation 
of the DNA repair machinery, leading to sustained 
genomic damage. Owing to the role of ATM in cell cycle 
arrest, ATM-deficient cells cannot induce checkpoint 
arrest following DNA damage, resulting in replication of 
damaged DNA and propagation of errors until the burden 
of damage becomes too severe for the genome and the 
cell is directed to a suicide route by an alternative, P53-
independent mechanism [67]. This propensity for ATM-
deficient cells to undergo apoptosis could explain the 
phenotype most commonly seen in A-T patients, due to 
death of cells in the neurons and the cells of the immune 
system, the main targets in the pathogenesis of the 
disease. The former are subjected to a massive (mainly 
oxidative) DNA damage which may not be promptly or 
completely repaired as neurons tend to inhibit selectively 
genome-wide DNA repair, focusing on the repair of 
actively transcribed genes [68]. During the formation of 
the T-cell receptor repertoire and the B-cell antibody 
repertoire in immune cells a significant amount of 
double-strand DNA breaks occurs naturally, which again, 
in ATM-deficient cells, triggers the apoptotic pathway 
[69]. 
Figure 1: Cellular responses to DNA damage. Depending upon the scale of DNA damage, one of the two pathways is activated. If the DNA 
damage is minor, sensor proteins are activated which recruit specialized DNA repair enzymes to the damaged site and DNA is repaired. However, 
if the DNA damage is extensive, the DNA Damage Response (DDR) pathway is activated which activates specialized transducer proteins that 
amplify the damaged signal and activate effector proteins. The effector proteins cause cell cycle arrest and increase in the production of DNA 
damage repair enzymes. The arrest at the cell cycle checkpoints may result in temporary halting of the cell cycle, a permanent arrest or induction 
of apoptotic pathways. 
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Targeting ATM signalling pathway as an 
anticancer strategy 
 
Decades of research efforts attempting to elucidate the 
DNA damage response pathways have added significant 
knowledge to our understanding of the mechanisms 
comprising DNA damage and repair signalling. These 
mechanisms involve sensing the DNA damage, 
generating a repair signal and amplification of the 
generated signal to elicit either a repair response, 
permanent arrest of the cell cycle, or apoptosis. 
Researchers have identified that cellular sensitivity to 
genotoxic agents in terms of cancer therapy can be 
achieved by modulating the function of key proteins 
involved in the above mentioned processes. 
A key consideration in developing strategies for 
cancer therapy is to ensure the specificity of the cytotoxic 
action towards cancer cells as compared with their 
normal counterparts. This degree of specificity in terms 
of cellular response is theoretically achievable through 
identifying vital differences between normal and cancer 
cells and then basing the therapeutic approach on 
exploiting those differences. 
Most, if not all cancer cells have mutations in genes 
affecting the cell cycle and DNA repair; these 
aberrations in vital cellular functions usually enhance 
their survival potential under stress, handicap their ability 
to sense the DNA damage and result in a failure to arrest 
the cell cycle to facilitate repair, leading to uncontrolled 
growth. However these abnormalities within cancer cells 
allow them to be distinguished from the surrounding 
normal cells and this can be exploited to achieve targeted 
cellular sensitivity.  More than 50% of all cancers have 
P53 mutations [70]; these render the cancer cell incapable 
of executing P53-mediated G1/S cell cycle arrest and 
repair of DNA upon genotoxic insults. However, they do 
retain a functional G2/M checkpoint such that damaged 
cells can still be arrested allowing for DNA repair, 
thereby enabling them to survive. Therefore, abrogation 
of the G2/M checkpoint in cancer cells via ATM 
inhibition (ATMChk1/Chk2G2/M arrest link) would 
disrupt the only available checkpoint and hence sensitise 
the cells against genotoxic agents [71]. In contrast, normal 
cells would be affected to a lesser extent by this treatment 
as they retain a wild type P53 and can therefore still exert 
G1/S arrest and repair of DNA. In such a scenario, ATM 
Figure 2: The ATM signalling pathway. ATM is present at the core of DNA damage pathway, activated upon DSBs and functions via multiple 
routes. While great deal of cross-talk exists between individual pathways, its major downstream substrates for DNA repair are MRN complex, 
BRCA1, RAD51 and, P53, for cell cycle arrest are SMC1, CIP/KIP family of proteins via P53 and checkpoint  kinases, for chromatic remodelling 
are Chk1 and for apoptosis are c-Abl, P53, Chk2, E2F1, P73 and  NFB. The figure is designed on the basis of data from 50, 51, 52, 53, 54, 55. 
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inhibition in P53 mutated cell lines (representing the 
majority of cancer cells) would theoretically cause more 
cytotoxicity after the same level of genotoxic insult as 
compared to cells carrying wild type P53 (normal cells). 
The working principle of this strategy is illustrated in 
Figure 4. Another potential substrate of ATM which 
could constitute a potential anticancer target is NF-kB, a 
transcription factor that is activated as part of the stress 
response and induces the transcription of genes that 
promote survival. In cancer cells, elevated or deregulated 
NF-kB activation is commonly found. Inhibition of ATM 
activity could prevent NF-kB-mediated cell survival and 
lead to NF-kB dependent sensitisation of such cells to IR 
triggering apoptosis [72].  
The concept of ATM inhibition-based anticancer 
therapeutic approach appears quite straightforward; 
nevertheless there are a number of challenges to 
overcome. Theoretically, inhibition of ATM function 
would disable the DDR mediated cell cycle arrest, DNA 
repair and apoptotic pathways, but there are other protein 
kinases sharing overlapping functions with ATM, such as 
DNA-PK and ATR. Thus, it may be necessary to inhibit 
all essential DDR kinases. However, a less selective 
inhibitor may be more cytotoxic in normal cells. 
Secondly, ATM itself can induce apoptosis via P53 
dependent and independent pathways [51, 73]. In these 
instances, ATM inhibition may rather desensitise the 
cells against genotoxic agents by enhancing, rather than 
reducing, survival. Hence, the design of an ATM 
inhibition-based strategy for maximising cellular 
sensitivity to genotoxic agents, requires dual 
consideration;  firstly it is essential to demonstrate, for 
any particular genotoxic agent, that the subsequent DNA 
repair and cell cycle arrest pathways, require ATM 
function. The second requirement is to carefully 
characterise the cellular response to the specific agent in 
terms of kinetics and dose response as well as the precise 
role of ATM in that context, in order to determine the 
Figure 3: The DNA damage pathway and its crosstalk with the cell cycle. Lines with arrow heads represent activation while lines with bar 
heads represent deactivation, dotted lines with arrow heads indicate activation via phosphorylation and dotted lines with bar heads denote 
phosphorylational inactivation. Grey lines with arrow heads represent dephosphorylation. After DNA damage, P53 and checkpoint kinases 
Chk1/Chk2 are activated. P53 activation results in concomitant rise in the CIP/KIP proteins, P21 and P27 which inhibit cyclin/CDK complexes, 
blocking the cell cycle progression which results in G1/S arrest. The activated Chk1/Chk2 kinases activate Wee1 protein kinase as well as inhibit 
the function of Cdc25 group of phosphatases, which normally dephosphorylate and activate cyclin/cdk complexes. The inactivation of 
cyclinB/CDK1 activity via both phosphorylational inactivation by Wee1 as well as inhibition of its activating phosphatases by Chk1/Chk2 result 
in G2/M arrest.  Thus in a normal cell, both G1/S and G2/M checkpoints are functional and may arrest the cell cycle upon DNA damage, to allow 
time for DNA repair.   
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most appropriate time to administer an ATM inhibitor, to 
maximise cancer cell cytotoxicity.  
In our own studies, we have determined the 
consequence of ATM inhibition on cell survival after 
subjecting a normal breast epithelial cell line, MCF10A 
and a breast cancer cell line, MCF7 to different levels of 
double stranded DNA damage. Time course, and dose 
response experiments were conducted with the DNA 
damaging agent, Doxorubicin (Dox) in the presence or 
absence of the small molecule ATM inhibitor KU55933 
(KU), and the extent of cell death was analysed using the 
Neutral red (NR) uptake assay (Supplementary fig. 1 A-
D). 
Time series treatment of 0.5μM Dox with and without 
ATM inhibition revealed different outcomes on cellular 
sensitivity towards genotoxicity and indicated context 
dependent dual roles of ATM in the following way: Dox 
treatment alone resulted in decreasing NR uptake 
indicating cell death to varying degrees depending upon 
time of treatment and starting at the first time point in 
both cell lines. While MCF7 cell line was more sensitive 
to Dox at early time points of treatment with 50% cell 
death reaching at 12hr of Dox treatment (Supplementary 
fig. 1B), MCF10A was less sensitive with 50% cell death 
at 20hr of treatment (Supplementary fig.1 A). However, at 
a final time point of 24 hr Dox treatment, we observed 
comparable cell deaths between the two cell lines tested. 
Interestingly, addition of 10μM ATM inhibitor (KU) 
along with Dox resulted in higher apoptosis (hence 
sensitisation to the genotoxic agent) only at earlier time 
points of 2, 4, 8 and 12 hr of treatments as compared to 
Dox alone in both cell lines. Furthering the treatment 
regime contrastingly resulted in a lower cell death with 
the addition of ATM inhibitor than without, at 16, 20 and 
24 hr time points (Supplementary figures 1A & 1B). 
Hence, it is indicated that at earlier time points, ATM 
kinase may mainly perform a cytoprotective function by 
triggering cell cycle arrest and DNA repair pathways as it 
ensured greater cell survival until 12 hr time point, as 
compared to that in ATM inhibited state. On the other 
hand, at a greater extent of DNA damage caused by 
longer genotoxic treatment beyond 12 hr, its function 
may have switched towards apoptosis, as there was 
higher cell death in functional ATM state than in 
inhibited state. 
Dose dependent treatment of Dox ranging from 0.1 to 
7μM with and without ATM inhibition similarly 
suggested a cytoprotective function of ATM at lower 
(0.1-0.25μM), while a role in apoptosis at higher (≥0.5μM) 
Dox levels in both MCF10A and MCF7 cell lines in the 
following way: Addition of KU with 0.1 and 0.25μM Dox 
resulted in greater sensitivity towards the genotoxic 
agent, and hence greater cell death in both cell lines as 
compared to Dox treatment alone. Increasing the dosage 
Figure 4: The principle of targeting ATM pathway for achieving targeted cellular sensitivity in cancer therapy. Lines with arrow heads 
indicate activation, while lines with bar heads indicate inhibition. Red arrow indicates DNA damage caused by radio or chemotherapy while red 
line with bar head indicates therapeutic inhibition of ATM. Cancer cells with P53 loss of function mutation have a dysfunctional G1/S checkpoint 
whereas the G2/M checkpoint may still be functional. When cells are exposed to genotoxic agents, DDR pathway is activated which will cause 
G1/S arrest via P53 pathway and G2/M arrest via checkpoint kinases Chk1 and Chk2 pathway. Normal cells can be arrest in either of these 
pathways allowing themselves time for DNA repair. However, cancer cells can only be arrested in G2/M pathway via ATMChk1/Chk2 
pathway. Disruption of G2/M checkpoint by way of ATM inhibition would result in failure of cancer cell to arrest in any checkpoint causing more 
sensitivity to genotoxic agents while normal cells with functional P53 would still be arrested and repaired.  
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to and above 0.5μM Dox showed reduced cell death in 
ATM inhibited state than ATM active state. For example, 
when ATM was inhibited, 50% cell death occurred at a 
relatively higher concentration of 5μM Dox, as compared 
to 1μM in ATM active state (Supplementary fig. 2A).  
Taken together, this data clearly demonstrates the 
different consequences of inhibiting ATM depending on 
the duration of treatment and dose of Dox used in the 
experiments. While these results are preliminary, they 
could have an impact on how DDR modulating drugs 
could be employed in the clinic. For example, in normal 
clinical practice, the physiologically achievable Dox 
concentration is maintained at approximately 100nM for 
up to 96hr by continuous infusion of the drug [74]. In our 
experiments, administration of an ATM inhibitor with 
100nM Dox for 12 hours resulted in greater cell death 
than Dox alone, implying that ATM was indeed 
performing a cytoprotective function under these 
conditions but not at 0.5µM concentration of Dox. This 
has significant implications for clinical use of ATM 
inhibitors. However it should be borne in mind that, these 
treatments were only performed for up to 12hr, thus 
additional experiments extending the time-course to 96hr, 
as is used in the clinic, would be worthwhile. Although 
these results are preliminary, these experiments serve to 
illustrate the necessity to carefully characterise the role of 
ATM or any other enzyme functioning in DDR 
signalling, in the context of the experimental setting 
before reaching the clinical setting. 
 
Inhibition of ATM activity: Research 
strategies employed  
 
Since ATM operates at the core of a signalling network 
that governs cell fate decision, manipulation of ATM 
function has become of increasing interest as a potential 
anticancer drug target. Theoretically, the attenuation of 
the DDR pathway should handicap the cellular 
machinery responsible for repairing damaged DNA, 
sensitise cancer cells to genotoxic insults and promote 
cell death after genotoxic treatments as illustrated in 
previous sections. This sensitisation of cancer cells could 
facilitate the use of reduced treatment regimens, which 
are less cytotoxic to normal cells but would still be 
sufficient to kill the cancer cells and achieve the desired 
efficacy. Such an approach would diminish the 
detrimental side effects of the drug on normal tissues and 
importantly has been demonstrated at the cellular level as 
well as in in vivo studies. Hence, one important 
therapeutic strategy is the identification of inhibitors of 
PIKK super family of kinases central to the decision 
making process of cell fate after genotoxic intervention.  
The discovery and characterization of these inhibitors 
has   not   only   helped  to  elucidate  the   function  of   
the   relevant   proteins   but   also  to   identify   the   most 
 therapeutically relevant targets. 
Table 3 is a list of recent inhibitors whose targets lie 
within the DNA damage response pathway. It is 
noteworthy that many of those listed in the table are 
either currently in clinical trials or have been in clinical 
trials. For example the Chk1 inhibitors AZD7762 and PF-
00477736, and the broader spectrum Chk1 and Chk2 
inhibitors UCN-01 and XL-844 as well as the PARP-1 
inhibitor AZD2281 have completed clinical trials whilst 
the DNA-PK inhibitor, CC-115, the alkyl guanine 
transferase inhibitor, O6 BG, and a specific Chk1 
inhibitor, LY2606368, are currently recruiting patients for 
clinical trials. In terms of exploiting the DNA damage 
response pathway for therapeutic intervention, the 
inhibitors of Poly ADP ribose polymerases have made 
the greatest progress and many novel drugs targeting 
these enzymes are already in clinical trials [93]. As yet, 
small molecule inhibitors of ATM have not reached any 
clinical trials.  
There are several reports that demonstrate increased 
cellular sensitivity towards genotoxic agents by way of 
modulating the ATM signalling pathway through 
inhibition of ATM kinase specifically. Upon DNA 
damage for example after treatments with 
chemotherapeutic agents or radiotherapy, some tumours 
undergo a premature senescence also called stress-
induced senescence. Although this permanent arrest of 
tumour cells is beneficial and prevents tumour 
metastasis, such senescent tumour cells resist apoptosis 
and may re-enter the cell cycle [94]. In order to identify 
the underlying signalling pathway, Crescenzi et al [95] 
studied drug induced tumour senescence in breast, lung 
and colon carcinoma cell lines and identified the 
ATM/ATR pathway to be constitutively active in these 
cells. Addition of the ATM kinase specific inhibitor 
KU55933 [75] or another ATM / ATR dual inhibitor 
CGK733 [79], caused increased apoptosis in these cell 
lines.  Of considerable note is that while this treatment 
was cytotoxic to cancer cells, it did not cause apoptosis in 
the normal senescent human fibroblasts. 
Morgan SE et al [35] over-expressed a mutated ATM 
protein encoding a truncated version of its functionally 
important Leucine zipper domain; this molecule had a 
dominant negative effect on ATM function. 
Overexpression of this functionally defective version of 
ATM in colon cancer cells increased the number of 
chromosomal breakages in such cells and resulted in the 
abrogation of the S-phase checkpoint, which led to an 
enhanced level of radiosensitivity. 
Inhibition of ATM expression, via ATM antisense 
RNA or siRNA mediated gene silencing, is another 
strategy adopted by several researchers. Guha C et al [96] 
explored the use of antisense RNA directed against the 
kinase domain of ATM for the attenuation of ATM levels 
in human glioblastoma cells. They found that attenuation 
of ATM levels resulted in increased radiosensitivity in 
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such cells independent of the status of P53. The resulting 
cells showed higher expression of P53 and P21 proteins, 
aberrant G2 checkpoint control and enhanced 
radiosensitivity after irradiation with a clinically relevant 
2 Gy dose. 
Collis GC et al [97] in a similar approach assessed the 
therapeutic potential of siRNA against ATM, ATR and 
DNA dependent protein kinase to test for their potential 
as radiotherapy and chemotherapy sensitizing agents 
against human prostate cancer cells. This approach 
reduced the respective protein levels by 90% after 48 
hours post treatment, accompanied by a significant 
increase in sensitivity of such cells towards radiotherapy. 
Interestingly, they also confirmed that such siRNA 
mediated silencing was a more potent sensitizing agent 
then some of the inhibitors of these kinases, e.g. 
wortmannin or LY294002.  
Recently, Neijenhuis S et al [98] reported that lung 
carcinoma cells expressing an aberrant β-Polymerase, a 
key enzyme involved in base excision repair, became 
 
Table 3. Different inhibitors that target the major proteins involved in DNA Damage response  
    
Target Compound Details Reference 
ATM KU55933 
ATM is a critical kinase of the DNA damage 
response and acts as a sensor and signal 
transducer for the damage pathway. KU55933 is 
the first potent and specific inhibitor of ATM. 
75 
ATM KU60019 An improved specific ATM kinase inhibitor 76 
ATM CP466722 
CP466722 is a reversible and specific inhibitor of 
ATM 
77 
ATR NU6027 A CDK2 and ATR inhibitor 78 
ATM and ATR CGK73 
ATM and ATR are important DNA damage 
response kinases that link the response to cell 
cycle. CGK733 is a potent but reversible inhibitor 
or both ATR and ATM. 
79 
ATM and ATR Caffeine 
Inhibits both ATM and ATR kinase activity leading 
to radiosensitisation. 
80 
DNA-PK NU7441 
DNA-PK is a DNA dependent kinase identifying 
double strand breaks activated in non-
homologous end joining repair. NU7441 is a 
specific DNA-PK inhibitor. 
81 
DNA-PK LY294002 
A general inhibitor of PI3-Kinases used to inhibit 
DNA-PK activity 
82 
ATM and DNA-PK Wortmannin A non-specific inhibitor of PI3-Like kinases 83 
DNA-PK CC-115 A dual DNA-PK and TOR kinase inhibitor 84 
Chk1 AZD7762 
An ATM/ATR dependent kinase with role in S and 
G2 arrest in response to DNA damage. AZD7762 
is ATP-competitive inhibitor of Chk1 
85 
Chk1 PF-00477736 
ATP competitive small molecular inhibitor of 
Chk1 
86 
Chk2 C3742 Small molecular inhibitor of Chk2 87 
Chk1 and Chk2 UCN-01 A general protein kinase inhibitor 88 
Chk1 and Chk2 XL-844 An inhibitor of the checkpoint kinases 89 
Chk1 LY2606368 A selective inhibitor of Chk1 kinase activity 90 
PARP-1 AZD2281 
Poly-ADP-Ribose polymerase 1is involved in S-
phase related DNA repair. 
91 
O6-alkylguanine-DNA 
alkyl transferase (AGT) 
O6-BG 
AGT is a repair factor in the direct repair. O6-BG 
is the first specific and potent inhibitor of AGT 
and sensitises several cancer types to different 
DNA damaging drugs 
92 
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dependent on homologous recombination repair after IR 
treatment. Blockade of ATM function in these cells, via 
KU55933 treatment, led to an increased radiosensitivity 
due to failure of cells to repair the damage by 
homologous recombination repair.  
Truman JP et al [99] exploited the link between the 
protein kinase C activator, 12-O-tetradecanoylphorbol 
12-acetate (TPA), and ATM in the radiosensitization of 
an otherwise radioresistant human prostate cancer cell 
line and to induce apoptosis. They reported that treatment 
of cells with TPA increased the levels of an apoptotic 
inducing regulatory enzyme ceramide synthase (CS) 
which was accompanied by a decrease in ATM activity, 
resulting in apoptosis induction after treatment with IR. 
This group also used antisense ATM oligonucleotides to 
suppress ATM expression in cancer cells. This resulted 
in higher levels of CS activation and apoptosis even with 
low radiation doses of 1Gy in the  radio resistant prostrate 
cancer cells.  
In another study, Gueven N et al. [26] established a 
negative link between EGF and ATM expression. The 
authors observed that the treatment of human 
lymphoblasts and fibroblasts with EGF down regulated 
the expression of both ATM and DNA-dependent protein 
kinases which, in turn, resulted in increased 
radiosensitization in cells with wild type ATM. As 
expected, no further radiosensitization was seen in 
irradiated A-T cells, which are already inherently 
radiosensitive. The group further demonstrated that the 
reduction of ATM protein levels following EGF 
treatment resulted from transcriptional suppression of 
ATM at the promoter level.   
A-T cells, which are highly chemo- and radio-
sensitive have disrupted NFB expression. Exploitation 
of the link between ATM and NFB pathway regulation 
(Fig. 2) is an interesting anticancer target and experiments 
have been successful using either a dominant negative 
form of the NFB inhibitor, I Kappa B alpha or inhibitors 
of ATM to disrupt the NFB pathway in achieving 
chemosensitization and apoptosis of cancer cells [72]. 
The body of data described here has compelled many 
pharmaceutical and biotechnology companies to fund 
projects in this area, and the large number of DDR 
inhibitors currently being studied in clinical trials serves 
to illustrate the significance of this strategy in ongoing 
efforts to combat cancer.  
 
New perspectives: Role of systems biology 
in the development and use of ATM 
inhibitors for anticancer treatment  
 
A prerequisite of a molecularly targeted anticancer 
approach is a detailed understanding of the underlying 
molecular mechanisms contributing to tumour 
development. Elucidation of these mechanisms would 
facilitate a better understanding of cancer biology, but 
would also provide for the identification of potential drug 
targets that would also afford cancer selectivity. The 
latter, as mentioned before, is based on characterising 
differences between normal and cancer cells. These 
differences are not only limited to DDR signalling 
pathways, but may also involve adaptive trafficking 
mechanisms, alteration in cell surface receptors, 
differential microRNA expression levels and changes in 
both the types and extents of molecular interactions 
governing key processes in a cell, all of which may 
influence drug efficacy. Additionally, a thorough 
understanding of the extracellular microenvironment, 
proliferation, growth and stress signals, serum levels and 
of the phase of the cell cycle are vital before a successful 
anticancer approach could be actualised. Owing to a 
central role of ATM in performing multiple functions 
after genotoxic insults, it is becoming clear that targeting 
the ATM signalling pathway may sensitise cancer cells 
to the genotoxic agents used in cancer therapy. However, 
recent reports have identified greater complexity in terms 
of ATM function and regulation [28, 29, 33] than was 
previously realised. In this more complex setting, the 
effect of manipulating ATM activity is not fully 
predictable. Thus, the efficacy of potential ATM 
inhibitors would have to be assessed in terms of the 
effects it exerts, not only on ATM activity, but on a 
number of other key proteins in the DNA repair, cell 
cycle and apoptotic pathways.  
We believe that this complexity in determining the 
absolute effects of manipulation of ATM activity could 
be best addressed by employing a systems biology 
approach to the problem, involving mathematical 
modelling [100]. Such a model could be capable of 
incorporating information from multiple cellular 
processes in which ATM is involved and which influence 
survival after genotoxic intervention. The model should 
be able to predict the global phosphorylation status of all 
the important substrates of ATM that function in 
different signalling pathways as well as the activity 
levels of a number of checkpoint and pro and anti-
apoptotic proteins and then ultimately predict the cellular 
response generated by the cell after the intervention. The 
model would also need to provide for varying levels of 
drug input over variable time courses as well as being 
capable of incorporating combinations of intervention 
strategies e.g. involving both IR and DNA damaging 
agents. The model could be calibrated initially using 
information gleaned from experimental assays. This 
would involve the quantitative measurement, at the 
molecular level, of a large number of inputs in terms of 
drug concentration, radiation dose, culture media, as well 
as measurement of the corresponding outputs with 
respect to a range of key molecules on the relevant 
pathways. A secondary calibration stage could be carried 
out along with results from initial clinical trials. This 
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would permit the model to be developed as a clinical 
application to be used in conjunction with the drug 
treatment regimes. Such an application would enable 
clinicians to determine the optimum timing and level of 
drug dose and radiation for use in the individual patient 
where the DDR pathway status has already been 
established by the measurement of key protein levels in 
that patient. 
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